St. Louis Trust Co Acquires Shares of 2,075 Intuitive Surgical, Inc. $ISRG

St. Louis Trust Co acquired a new stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund acquired 2,075 shares of the medical equipment provider’s stock, valued at approximately $1,175,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Vanguard Group Inc. increased its stake in shares of Intuitive Surgical by 0.8% in the 3rd quarter. Vanguard Group Inc. now owns 33,599,661 shares of the medical equipment provider’s stock valued at $15,026,776,000 after buying an additional 263,828 shares during the period. Capital World Investors increased its stake in shares of Intuitive Surgical by 1.5% in the 3rd quarter. Capital World Investors now owns 7,728,492 shares of the medical equipment provider’s stock valued at $3,456,223,000 after buying an additional 116,034 shares during the period. Fisher Asset Management LLC increased its stake in shares of Intuitive Surgical by 1.1% in the 3rd quarter. Fisher Asset Management LLC now owns 3,889,439 shares of the medical equipment provider’s stock valued at $1,739,475,000 after buying an additional 40,702 shares during the period. Amundi increased its stake in shares of Intuitive Surgical by 29.7% in the 3rd quarter. Amundi now owns 3,227,472 shares of the medical equipment provider’s stock valued at $1,451,362,000 after buying an additional 739,444 shares during the period. Finally, Jennison Associates LLC increased its stake in shares of Intuitive Surgical by 11.1% in the 4th quarter. Jennison Associates LLC now owns 3,209,137 shares of the medical equipment provider’s stock valued at $1,817,527,000 after buying an additional 321,759 shares during the period. 83.64% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

ISRG has been the subject of several research reports. UBS Group lowered their target price on Intuitive Surgical from $570.00 to $550.00 and set a “neutral” rating for the company in a research note on Tuesday, March 17th. TD Cowen lowered their target price on Intuitive Surgical from $660.00 to $585.00 and set a “buy” rating for the company in a research note on Wednesday, April 22nd. Truist Financial lowered their target price on Intuitive Surgical from $650.00 to $580.00 and set a “buy” rating for the company in a research note on Wednesday, April 15th. Barclays set a $651.00 price objective on Intuitive Surgical and gave the stock an “overweight” rating in a research note on Thursday, April 23rd. Finally, Citigroup raised Intuitive Surgical from a “neutral” rating to a “buy” rating and set a $590.00 price objective for the company in a research note on Wednesday, March 11th. Nineteen analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $579.33.

Intuitive Surgical Price Performance

Shares of NASDAQ:ISRG opened at $438.10 on Friday. The business’s 50 day simple moving average is $458.62 and its 200 day simple moving average is $510.61. Intuitive Surgical, Inc. has a 1 year low of $417.74 and a 1 year high of $603.88. The company has a market capitalization of $155.16 billion, a P/E ratio of 53.10, a P/E/G ratio of 3.50 and a beta of 1.51.

Intuitive Surgical (NASDAQ:ISRG) last released its earnings results on Tuesday, April 21st. The medical equipment provider reported $2.50 earnings per share for the quarter, topping the consensus estimate of $2.08 by $0.42. Intuitive Surgical had a return on equity of 15.98% and a net margin of 28.15%.The firm had revenue of $2.77 billion during the quarter, compared to analysts’ expectations of $2.62 billion. During the same period in the prior year, the company earned $1.81 earnings per share. The company’s quarterly revenue was up 23.0% on a year-over-year basis. On average, sell-side analysts anticipate that Intuitive Surgical, Inc. will post 8.57 EPS for the current fiscal year.

Insider Buying and Selling

In other news, SVP Mark Brosius sold 2,362 shares of the stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $498.68, for a total value of $1,177,882.16. Following the completion of the transaction, the senior vice president directly owned 3,554 shares in the company, valued at approximately $1,772,308.72. This represents a 39.93% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Amy L. Ladd sold 500 shares of the stock in a transaction on Tuesday, April 28th. The shares were sold at an average price of $473.46, for a total value of $236,730.00. Following the completion of the transaction, the director owned 239 shares of the company’s stock, valued at $113,156.94. The trade was a 67.66% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 5,701 shares of company stock worth $2,783,807 in the last ninety days. Insiders own 0.60% of the company’s stock.

Key Stories Impacting Intuitive Surgical

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Intuitive unveiled more than 100 upcoming upgrades for its da Vinci 5 robotic surgery system, including improved force-feedback tools, telecollaboration features, and security/reliability enhancements, which could strengthen the company’s competitive moat and support future procedure growth. Intuitive Surgical’s Da Vinci 5 Upgrades Aim To Deepen Moat For Investors
• Positive Sentiment: Intuitive also announced innovations tied to its “Quintuple Aim” strategy, reinforcing product development momentum and the company’s push to improve surgeon autonomy and operating-room efficiency. Intuitive Announces Innovations to Advance Quintuple Aim
• Positive Sentiment: Wall Street commentary remains moderately optimistic, with analysts still bullish on Intuitive Surgical’s long-term prospects despite recent underperformance versus the broader market. Are Wall Street Analysts Bullish on Intuitive Surgical Stock?
• Neutral Sentiment: Investor interest continues around the SP platform, where strong procedure growth suggests an important future opportunity, but it remains unclear whether this is true addressable-market expansion or mostly a shift within existing robotic procedures. ISRG’s SP Platform: Early-Stage Growth or Next TAM Expansion Driver?
• Neutral Sentiment: There was also minor insider selling by an executive, but the transactions were very small and made under a pre-arranged 10b5-1 plan, so the signal for investors is limited. Mark Brosius insider transaction
• Negative Sentiment: The stock has also been hurt by recent weakness after earnings, with market commentary noting a roughly 7% decline since the last report, reflecting concern that the shares may need more proof of sustained acceleration. Why Is Intuitive Surgical (ISRG) Down 7.2% Since Last Earnings Report?
• Negative Sentiment: Several articles also point out that ISRG has significantly lagged the market over the past six months, which may be keeping valuation-sensitive investors on the sidelines. 3 Big Reasons ISRG Should Be On Your Watchlist

Intuitive Surgical Company Profile

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.